An Updated and Focused Review on Heterocyclic Inhibitors for SARS-CoV and SARS-CoV-2 3CLpro

被引:1
作者
Manaithiya, Ajay [1 ]
Alam, Ozair [1 ]
Mittal, Shruti [1 ]
Naim, Mohd. Javed [1 ]
Imran, Mohd [2 ]
Alshrari, Ahmed Subeh [3 ]
Sheikh, Aadil A. A. [1 ]
Khan, Imran A. A. [4 ]
机构
[1] Jamia Hamdard, Sch Pharmaceut Educ & Res, Med Chem & Mol Modelling Lab, Dept Pharmaceut Chem, New Delhi 110062, India
[2] Northern Border Univ, Fac Pharm, Dept Pharmaceut Chem, Rafha 91911, Saudi Arabia
[3] Northern Border Univ, Fac Appl Med Sci, Med Lab Technol, Ar Ar, Saudi Arabia
[4] Jamia Hamdard, Sch Chem & Life Sci, Dept Chem, New Delhi 110062, India
关键词
SARS-CoV; SARS-CoV-2; biological activity; structure-activity relationship; molecular docking; heterocyclic inhibitors; ACUTE RESPIRATORY SYNDROME; 3CL PROTEASE INHIBITORS; CORONAVIRUS DISEASE 2019; ANTIVIRAL ACTIVITY; BIOLOGICAL EVALUATION; ISATIN DERIVATIVES; COVID-19; INFECTION; VIRAL-RNA; IN-VITRO; IDENTIFICATION;
D O I
10.2174/1389557522666220511125102
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background SARS-CoV and SARS-CoV-2 are exceedingly contagious and typically result in major respiratory illnesses (acute respiratory syndrome). The public health is facing enormous challenges across all the nations due to these newly emerging pathogens. Reliable and systematic examination of SARS-CoV and COVID-19 will assist in identifying infectious persons accurately. Based on the biological, chemical, and genetic link of SARS CoV-2 towards SARS-CoV, the recurrence of different anti-SARS-CoV natural drug molecules may be beneficial in the advancement of anti-COVID-19 herbal drug molecules. Here in this review, we evaluated SAR research that has recently been published as well as molecular docking analysis of previously synthesised compounds that have been targeted against SARS-CoV and SARS-CoV-2, respectively. This investigation might assist scientists in creating novel and revolutionary molecules that could target SAR-CoV-2. Objectives The review highlights the heterocyclic inhibitors' ability to successfully inhibit SARS-CoV and SARS-CoV-2. The meticulously described structure-activity relationship of potential SARS-CoV and SARS-CoV-2 inhibiting compounds has been addressed in this review. Evidence Acquisition We conducted a thorough literature assessment employing electronic databases for scientific articles highlighting potential heterocyclic inhibitors for SARS-CoVand SARS-CoV-2, published from 2010 to 2021. We recovered 415 articles, but only 220 were involved and conversed in this manuscript. The article apprehended appropriate research considering three areas: 1) SAR activity, 2) Molecular docking, and 3) Biological activity and future prospects on SARS-CoV-2. Methods The potential compounds with decent inhibitory activity have been discussed and reviewed along with their inhibition potential, expressed in terms of IC50 value. Results Heterocyclic scaffolds reflect an extensive spectrum of therapeutic activity and might function as an initiating concept for the designing and discovery of potential inhibitors for SARS-CoV and SARS-CoV-2 treatment. Conclusion The points highlighted here may prove to be a vital tool for medicinal chemists working/investigating more potent and efficacious scaffolds in treating SARS-CoV and SARS-CoV-2.
引用
收藏
页码:576 / 632
页数:57
相关论文
共 50 条
  • [41] Virtual screening and molecular dynamics simulation analysis of Forsythoside A as a plant-derived inhibitor of SARS-CoV-2 3CLpro
    Bibi, Shabana
    Khan, Muhammad Saad
    El-Kafrawy, Sherif A.
    Alandijany, Thamir A.
    El-Daly, Mai M.
    Yousafi, Qudsia
    Fatima, Dua
    Faizo, Arwa A.
    Bajrai, Leena H.
    Azhar, Esam I.
    SAUDI PHARMACEUTICAL JOURNAL, 2022, 30 (07) : 979 - 1002
  • [42] Synthesis, in silico and in vitro studies of novel quinazolinone derivatives as potential SARS-CoV-2 3CLpro inhibitors
    Alamri, Mubarak A.
    Afzal, Obaid
    Akhtar, Md Jawaid
    Karim, Shahid
    Husain, Mohammed
    Alossaimi, Manal A.
    Riadi, Yassine
    ARABIAN JOURNAL OF CHEMISTRY, 2024, 17 (01)
  • [43] An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro/Mpro) of SARS-CoV-2
    Yan, Fangfang
    Gao, Feng
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2021, 19 : 4868 - 4883
  • [44] Design and Synthesis of Michael Acceptor-Based Peptidyl β-Nitrostyrenes as 3CLpro Inhibitors of SARS-CoV-2
    Sharma, Sweta
    Yakkala, Prasanna Anjaneyulu
    Aboti, Jyoti
    Latief, Insha
    Ansari, Mairaj Ahmed
    Khan, Wajihul Hasan
    Shafi, Syed
    CHEMISTRYSELECT, 2023, 8 (24):
  • [45] SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii
    Ryu, Young Bae
    Park, Su-Jin
    Kim, Young Min
    Lee, Ju-Yeon
    Seo, Woo Duck
    Chang, Jong Sun
    Park, Ki Hun
    Rho, Mun-Chual
    Lee, Woo Song
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (06) : 1873 - 1876
  • [46] SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge
    Ezhilan, Madeshwari
    Suresh, Indhu
    Nesakumar, Noel
    MEASUREMENT, 2021, 168
  • [47] Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
    Rawson, Jonathan M. O.
    Duchon, Alice
    Nikolaitchik, Olga A.
    Pathak, Vinay K.
    Hu, Wei-Shau
    VIRUSES-BASEL, 2021, 13 (02):
  • [48] Unique tRNA Fragment Upregulation with SARS-CoV-2 but Not with SARS-CoV Infection
    Imirowicz, Isabella
    Saifee, Azeem
    Henry, Leanne
    Tunkle, Leo
    Popescu, Alexander
    Huang, Philip
    Jakpor, Jibiana
    Barbano, Ava
    Goru, Rohit
    Gunawan, Audrey
    Sicilia, Maria
    Ono, Mori
    Bao, Xiaoyong
    Lee, Inhan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [49] SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
    Abdelghany, T. M.
    Ganash, Magdah
    Bakri, Marwah M.
    Qanash, Husam
    Al-Rajhi, Aisha M. H.
    Elhussieny, Nadeem, I
    BIOMEDICAL JOURNAL, 2021, 44 (01) : 86 - 93
  • [50] SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
    Elshabrawy, Hatem A.
    VACCINES, 2020, 8 (02) : 1 - 33